A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

Item

http://www.wikidata.org/entity/Q33343716

Q33343716

about

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Overview of the clinical efficacy of investigational anticancer drugs.Farnesyl transferase inhibitors in the treatment of breast cancer.Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.Therapeutic silencing of KRAS using systemically delivered siRNAs.Lonafarnib in cancer therapy.Biological agents versus chemotherapy in the treatment of colorectal cancer.Genetics of melanoma Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas The new paradigm in the treatment of colorectal cancer: are we hitting the right target?Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma Lonafarnib for cancer and progeria.New target agents in the treatment of colorectal cancer patients.Recent advances in oral anticancer agents for colon cancer.In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus.The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.Working together: Farnesyl transferase inhibitors and statins block protein prenylation.Molecular and clinical aspects of hepatitis D virus infections.RhoB: Team Oncogene or Team Tumor Suppressor?

P2860

Q27853172-12BED613-DE7D-48A0-BFF7-626FD763EDB0 Q33644407-841B74F1-6047-492D-93E6-677E3B6E959E Q33914284-70CEEB7C-B9B4-4542-8258-5F539F0322D5 Q34651253-E4C4C7D1-3B44-4D96-8009-91F69F3F9465 Q34659415-0E03940D-88F3-4691-B03C-0918632BD687 Q35067125-20050225-D781-4D84-8A14-8F048D3CF906 Q35073354-5F8AF771-D0D9-49BB-B7B0-F7C310EC3EA5 Q35383553-62A8043D-A20E-45F8-94AA-684F09D930DD Q35525553-0D8C3BF5-81B4-4B25-BD3B-8CE8EC20B796 Q35559932-2636836D-C700-471D-9D9B-4D8CC397A87B Q36491847-D5E7F2C6-B897-4844-959B-944616EA69D0 Q36521850-7F256B0C-BD6E-4151-9B27-057FD55084A8 Q36563659-FAE4B29A-0DA3-4E50-A62D-0D0820879F7E Q36693797-35468EE6-7A71-4DFE-BE5A-C15AF7DAA59B Q36736346-87E65B01-26FF-4281-B2D1-F1D5831CCF90 Q37727000-E971B107-FE50-4265-AA99-9F1FDA811814 Q38012480-06E9CDB0-7C65-4269-BFB5-8B68AD2178E5 Q38089157-D241392F-A3A1-4FFB-A7EC-45401E41BA94 Q38167885-172D75F1-7E29-49AA-858E-7213E1AB1D73 Q39793276-F04E8133-5A31-4EBF-A9BD-5A6538D4DC68 Q40134426-9DBCC64E-FB99-45F7-BB53-E833D8CB7FEA Q40149906-9C2B199D-AC30-4815-A657-FA7E219C8ECA Q42969554-518CD689-6C24-4FC3-9925-0C89DAF3658E Q49550467-31375A5C-748C-41CD-B994-CB426E22F612

P2860

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

Item

http://www.wikidata.org/entity/Q33343716

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu